Scientists test aggressive new drug cocktail for Tough-to-Treat leukemia
NCT ID NCT03900949
Summary
This early-stage study aimed to find the safest dose of a four-drug combination for adults newly diagnosed with a specific genetic type of acute myeloid leukemia (AML). Researchers tested adding two newer drugs (gemtuzumab ozogamicin and midostaurin) to a standard two-drug chemotherapy backbone. The main goal was to see how well patients tolerated this intensive treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University Knight Cancer Institute - Northwest Portland
Portland, Oregon, 97210, United States
Conditions
Explore the condition pages connected to this study.